These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

256 related items for PubMed ID: 9551704

  • 1. An interaction study with cimetidine and the new angiotensin II antagonist valsartan.
    Schmidt EK, Antonin KH, Flesch G, Racine-Poon A.
    Eur J Clin Pharmacol; 1998 Feb; 53(6):451-8. PubMed ID: 9551704
    [Abstract] [Full Text] [Related]

  • 2. Pharmacokinetic and pharmacodynamic interaction of single doses of valsartan and atenolol.
    Czendlik CH, Sioufi A, Preiswerk G, Howald H.
    Eur J Clin Pharmacol; 1997 Feb; 52(6):451-9. PubMed ID: 9342580
    [Abstract] [Full Text] [Related]

  • 3. Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin II receptor antagonist, in man.
    Flesch G, Müller P, Lloyd P.
    Eur J Clin Pharmacol; 1997 Feb; 52(2):115-20. PubMed ID: 9174680
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Pharmacokinetics, disposition and biotransformation of [14C]-radiolabelled valsartan in healthy male volunteers after a single oral dose.
    Waldmeier F, Flesch G, Müller P, Winkler T, Kriemler HP, Bühlmayer P, De Gasparo M.
    Xenobiotica; 1997 Jan; 27(1):59-71. PubMed ID: 9041679
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Vildagliptin, a novel dipeptidyl peptidase IV inhibitor, has no pharmacokinetic interactions with the antihypertensive agents amlodipine, valsartan, and ramipril in healthy subjects.
    He YL, Ligueros-Saylan M, Sunkara G, Sabo R, Zhao C, Wang Y, Campestrini J, Pommier F, Dole K, Marion A, Dole WP, Howard D.
    J Clin Pharmacol; 2008 Jan; 48(1):85-95. PubMed ID: 17986525
    [Abstract] [Full Text] [Related]

  • 8. Influence of the antacid Maalox and the H2-antagonist cimetidine on the pharmacokinetics of cerivastatin.
    Mück W, Ritter W, Dietrich H, Frey R, Kuhlmann J.
    Int J Clin Pharmacol Ther; 1997 Jun; 35(6):261-4. PubMed ID: 9208343
    [Abstract] [Full Text] [Related]

  • 9. Evaluation of the pharmacokinetic and pharmacodynamic drug interactions between cilnidipine and valsartan, in healthy volunteers.
    Lee J, Lee H, Jang K, Lim KS, Shin D, Yu KS.
    Drug Des Devel Ther; 2014 Jun; 8():1781-8. PubMed ID: 25336921
    [Abstract] [Full Text] [Related]

  • 10. Results of a single-center, single-dose, randomized-sequence, open-label, two-way crossover bioequivalence study of two formulations of valsartan 160-mg tablets in healthy volunteers under fasting conditions.
    Spínola AC, Almeida S, Filipe A, Neves R, Trabelsi F, Farré A.
    Clin Ther; 2009 Sep; 31(9):1992-2001. PubMed ID: 19843489
    [Abstract] [Full Text] [Related]

  • 11. Pharmacokinetic interactions of valsartan and hydrochlorothiazide: an open-label, randomized, 4-period crossover study in healthy Egyptian male volunteers.
    Hedaya MA, Helmy SA.
    Clin Ther; 2013 Jun; 35(6):846-61. PubMed ID: 23795576
    [Abstract] [Full Text] [Related]

  • 12. Pharmacokinetic properties and bioequivalence of 2 formulations of valsartan 160-mg tablets: A randomized, single-dose, 2-period crossover study in healthy Korean male volunteers.
    Kim JE, Ki MH, Yoon IS, Cho HJ, Kim RS, Tae Kim G, Kim DD.
    Clin Ther; 2014 Feb 01; 36(2):273-9. PubMed ID: 24529292
    [Abstract] [Full Text] [Related]

  • 13. Pharmacokinetic and bioequivalence study of two brands of valsartan tablets in healthy male volunteers.
    Zakeri-Milani P, Valizadeh H, Islambulchilar Z, Nemati M.
    Arzneimittelforschung; 2010 Feb 01; 60(2):76-80. PubMed ID: 20329655
    [Abstract] [Full Text] [Related]

  • 14. Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril.
    Maeda K, Ieiri I, Yasuda K, Fujino A, Fujiwara H, Otsubo K, Hirano M, Watanabe T, Kitamura Y, Kusuhara H, Sugiyama Y.
    Clin Pharmacol Ther; 2006 May 01; 79(5):427-39. PubMed ID: 16678545
    [Abstract] [Full Text] [Related]

  • 15. The effect of age on the pharmacokinetics of valsartan.
    Sioufi A, Marfil F, Jaouen A, Cardot JM, Godbillon J, Ezzet F, Lloyd P.
    Biopharm Drug Dispos; 1998 May 01; 19(4):237-44. PubMed ID: 9604123
    [Abstract] [Full Text] [Related]

  • 16. Pharmacokinetics and bioequivalence study of three oral formulations of valsartan 160 mg: a single-dose, randomized, open-label, three-period crossover comparison in healthy Indian male volunteers.
    Iqbal M, Khuroo A, Batolar LS, Tandon M, Monif T, Sharma PL.
    Clin Ther; 2010 Mar 01; 32(3):588-96. PubMed ID: 20399995
    [Abstract] [Full Text] [Related]

  • 17. Pharmacokinetics of multiple doses of valsartan in patients with heart failure.
    Prasad PP, Yeh CM, Gurrieri P, Glazer R, McLeod J.
    J Cardiovasc Pharmacol; 2002 Nov 01; 40(5):801-7. PubMed ID: 12409989
    [Abstract] [Full Text] [Related]

  • 18. The effect of valsartan on the angiotensin II pressor response in healthy normotensive male subjects.
    Morgan JM, Palmisano M, Piraino A, Hirschhorn W, Spencer S, Prasad PP, Ortiz M, Lloyd P.
    Clin Pharmacol Ther; 1997 Jan 01; 61(1):35-44. PubMed ID: 9024172
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.